Trastuzumab not for ductal carcinoma in situ?

Zeina Nahleh, Azadeh Namakydoust, Rania Bakkar, John W Bishop

Research output: Contribution to journalArticle

Abstract

Ductal carcinoma in situ (DCIS) is a preinvasive breast lesion accounting for approximately 30% of all newly detected breast cancers in the US. DCIS has been separated into two groups by architecture (comedo versus noncomedo) and nuclear grade. The expression of biological markers in DCIS, however, would reflect the true biologic potential of the lesion. Patients with estrogen receptor (ER)-negative, human epidermal growth factor-2 (HER-2)-positive DCIS pose a treatment challenge. They are not candidates for tamoxifen; trastuzumab has an undetermined role in DCIS. In this report, we present a case of a 45-year-old woman diagnosed with invasive breast cancer and ER-negative/HER-2- positive DCIS who developed recurrence and progression of DCIS as manifested by a new palpable mass while receiving trastuzumab as part of adjuvant treatment for invasive breast cancer. The potential clinical implications are discussed.

Original languageEnglish (US)
Pages (from-to)1231-1235
Number of pages5
JournalAnti-Cancer Drugs
Volume18
Issue number10
DOIs
StatePublished - Nov 2007
Externally publishedYes

Fingerprint

Carcinoma, Intraductal, Noninfiltrating
Breast Neoplasms
Epidermal Growth Factor
Estrogen Receptors
Tamoxifen
Trastuzumab
Breast
Biomarkers
Recurrence
Therapeutics

Keywords

  • Ductal carcinoma in situ
  • Trastuzumab

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research
  • Oncology

Cite this

Trastuzumab not for ductal carcinoma in situ? / Nahleh, Zeina; Namakydoust, Azadeh; Bakkar, Rania; Bishop, John W.

In: Anti-Cancer Drugs, Vol. 18, No. 10, 11.2007, p. 1231-1235.

Research output: Contribution to journalArticle

Nahleh, Z, Namakydoust, A, Bakkar, R & Bishop, JW 2007, 'Trastuzumab not for ductal carcinoma in situ?', Anti-Cancer Drugs, vol. 18, no. 10, pp. 1231-1235. https://doi.org/10.1097/CAD.0b013e3282a4a61c
Nahleh, Zeina ; Namakydoust, Azadeh ; Bakkar, Rania ; Bishop, John W. / Trastuzumab not for ductal carcinoma in situ?. In: Anti-Cancer Drugs. 2007 ; Vol. 18, No. 10. pp. 1231-1235.
@article{b7063a0cd1e442af8a26607a5b8e87c1,
title = "Trastuzumab not for ductal carcinoma in situ?",
abstract = "Ductal carcinoma in situ (DCIS) is a preinvasive breast lesion accounting for approximately 30{\%} of all newly detected breast cancers in the US. DCIS has been separated into two groups by architecture (comedo versus noncomedo) and nuclear grade. The expression of biological markers in DCIS, however, would reflect the true biologic potential of the lesion. Patients with estrogen receptor (ER)-negative, human epidermal growth factor-2 (HER-2)-positive DCIS pose a treatment challenge. They are not candidates for tamoxifen; trastuzumab has an undetermined role in DCIS. In this report, we present a case of a 45-year-old woman diagnosed with invasive breast cancer and ER-negative/HER-2- positive DCIS who developed recurrence and progression of DCIS as manifested by a new palpable mass while receiving trastuzumab as part of adjuvant treatment for invasive breast cancer. The potential clinical implications are discussed.",
keywords = "Ductal carcinoma in situ, Trastuzumab",
author = "Zeina Nahleh and Azadeh Namakydoust and Rania Bakkar and Bishop, {John W}",
year = "2007",
month = "11",
doi = "10.1097/CAD.0b013e3282a4a61c",
language = "English (US)",
volume = "18",
pages = "1231--1235",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Trastuzumab not for ductal carcinoma in situ?

AU - Nahleh, Zeina

AU - Namakydoust, Azadeh

AU - Bakkar, Rania

AU - Bishop, John W

PY - 2007/11

Y1 - 2007/11

N2 - Ductal carcinoma in situ (DCIS) is a preinvasive breast lesion accounting for approximately 30% of all newly detected breast cancers in the US. DCIS has been separated into two groups by architecture (comedo versus noncomedo) and nuclear grade. The expression of biological markers in DCIS, however, would reflect the true biologic potential of the lesion. Patients with estrogen receptor (ER)-negative, human epidermal growth factor-2 (HER-2)-positive DCIS pose a treatment challenge. They are not candidates for tamoxifen; trastuzumab has an undetermined role in DCIS. In this report, we present a case of a 45-year-old woman diagnosed with invasive breast cancer and ER-negative/HER-2- positive DCIS who developed recurrence and progression of DCIS as manifested by a new palpable mass while receiving trastuzumab as part of adjuvant treatment for invasive breast cancer. The potential clinical implications are discussed.

AB - Ductal carcinoma in situ (DCIS) is a preinvasive breast lesion accounting for approximately 30% of all newly detected breast cancers in the US. DCIS has been separated into two groups by architecture (comedo versus noncomedo) and nuclear grade. The expression of biological markers in DCIS, however, would reflect the true biologic potential of the lesion. Patients with estrogen receptor (ER)-negative, human epidermal growth factor-2 (HER-2)-positive DCIS pose a treatment challenge. They are not candidates for tamoxifen; trastuzumab has an undetermined role in DCIS. In this report, we present a case of a 45-year-old woman diagnosed with invasive breast cancer and ER-negative/HER-2- positive DCIS who developed recurrence and progression of DCIS as manifested by a new palpable mass while receiving trastuzumab as part of adjuvant treatment for invasive breast cancer. The potential clinical implications are discussed.

KW - Ductal carcinoma in situ

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=34748865964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34748865964&partnerID=8YFLogxK

U2 - 10.1097/CAD.0b013e3282a4a61c

DO - 10.1097/CAD.0b013e3282a4a61c

M3 - Article

C2 - 17893526

AN - SCOPUS:34748865964

VL - 18

SP - 1231

EP - 1235

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 10

ER -